The medication was created by Axsome Therapeutics, a pharmaceutical company that develops treatments for central nervous system disorders.
“[Auvelity] represents the first new oral non-monoamine-based mechanism of action approved to treat major depressive disorder in over sixty years,” Maurizio Fava, MD, psychiatrist-in-chief, Massachusetts General Hospital, said in a Aug.19 news release from Axsome.
“Given the debilitating nature of depression, the efficacy of Auvelity observed at one week and sustained thereafter may have a significant impact on the current treatment paradigm for this condition,” Dr. Fava said.